VSTM, US92337C2035

Verastem stock trades at 7.55 euros after Q3 update

Published on 11/08/2026 at 13:58 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Verastem stock traded at 7.55 euros on Lang & Schwarz after its latest quarterly update. Product revenue rose as refills supported demand.

Verastem advances its oncology pipeline

Third-quarter product revenue reached USD 24 million, according to MarketBeat.
Verastem plans to begin a Phase 3 pancreatic cancer trial by the end of 2026.
An October financing is expected to extend the company's funding into the first half of 2028.

VSTM, US92337C2035, Illustration mit AI erstellt.

Verastem stock traded at 7.55 euros on Lang & Schwarz at 13:04 CET on Saturday, November 7, 2026. The quote followed the company's latest quarterly update, which highlighted commercial revenue growth alongside continued investment in its oncology pipeline.

The real-time quote of Verastem stock is available through the company's market page.

Revenue growth meets wider losses

According to MarketBeat, Verastem generated USD 24 million in third-quarter product revenue, an increase of 114 percent from the same period a year earlier. Refills of the company's ovarian cancer CO-PACK helped offset slower new-patient starts.

The non-GAAP adjusted net loss widened to USD 72.8 million from USD 39.1 million a year earlier. Research and development expenses reached USD 68.8 million during the quarter, while selling, general and administrative expenses were USD 26.5 million.

Phase 3 plans set next catalyst

Verastem plans to start a Phase 3 study of VS-7375 in first-line pancreatic cancer by the end of 2026. The company also expects to pursue Phase 3 studies in colorectal and non-small cell lung cancer during the first half of 2027, subject to further alignment with the US Food and Drug Administration.

The company said an October offering raised approximately USD 250 million. Together with cash, equivalents and investments held at the end of the quarter, the financing produced a stated pro forma cash balance of USD 422.8 million and is expected to support operations into the first half of 2028. CEO Dan Paterson plans to retire at the end of 2026, with Michael Bailey set to succeed him.